Physician profile
Mohammad S Sarwar
NPI 1407823644
$5,930.51
in general payments reported to CMS, 2019-2025
29 companies · $581 in 2025
The $581 reported for 2025 was more than what 76% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $109 · 2021: $1,475 · 2022: $445 · 2023: $897 · 2024: $2,226 · 2025: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427 · Travel and Lodging: $1,216 · Education: $61.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.27 |
| Travel and Lodging | $1,216.07 |
| Education | $61.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,728.47 | 2021-2025 | Minimed 780g |
| Dexcom, INC. | $755.43 | 2022-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $165.63 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Janssen Pharmaceuticals, INC | $141.63 | 2019-2021 | |
| Insulet Corporation | $134.84 | 2023-2025 | Omnipod |
| Merck Sharp & Dohme LLC | $111.13 | 2023 | Verquvo |
| Astellas Pharma US INC | $104.96 | 2022-2023 | Veozah |
| Sanofi-Aventis U.S. LLC | $102.09 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $93.24 | 2019-2024 | |
| Gilead Sciences, INC. | $79.82 | 2020-2025 | |
| Mannkind Corporation | $59.40 | 2022 | |
| Corcept Therapeutics | $57.38 | 2021-2025 | Korlym |
| Vanda Pharmaceuticals INC. | $44.03 | 2019-2025 | Fanapt |
| Xeris Pharmaceuticals, INC. | $36.82 | 2023-2024 | Gvoke Hypopen |
| Inspire Medical Systems, INC. | $35.74 | 2025 | Inspire |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $34.24 | 2025 | Breztri, Farxiga |
| Beta Bionics, INC. | $27.32 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $25.84 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lundbeck LLC | $24.72 | 2025 | Rexulti |
| Pfizer INC. | $22.73 | 2021 | |
| Amicus Therapeutics, INC. | $21.00 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.26 | 2025 | |
| Amgen INC. | $17.62 | 2020 | |
| Global Blood Therapeutics, INC. | $17.26 | 2021 | |
| Redhill Biopharma INC. | $15.27 | 2020 | |
| Abbott Laboratories | $14.67 | 2024 | Freestyle Libre 3 |
| Paratek Pharmaceuticals, INC. | $14.32 | 2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.66 | 2022 | |
| Cequr Corporation | $11.99 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Sarwar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.